FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366064463> ?p ?o ?g. }

• W4366064463 endingPage "297" @default.
• W4366064463 startingPage "290" @default.
• W4366064463 abstract "Two prior double-blind, placebo-controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, onset, and durability of any effect of GA on disease activity monitored with magnetic resonance imaging (MRI) in patients with RRMS. Two hundred thirty-nine eligible patients were randomized to receive either 20 mg GA (n = 119) or placebo (n = 120) by daily subcutaneous injection. Eligibility required one or more relapses in the 2 years before entry and at least one enhancing lesion on a screening MRI. The study was a randomized, double-blind, placebo-controlled phase during which all patients studied underwent monthly MRI scans and clinical assessments over 9 months. The primary outcome measure was the total number of enhancing lesions on T1-weighted images. Secondary outcome measures included the proportion of patients with enhancing lesions, the number of new enhancing lesions and change in their volume; the number of new lesions detected on T2-weighted images and change in their volume, and the change in volume of hypointense lesions seen on unenhanced T1-weighted images. Clinical measures of disease activity were also evaluated. The active treatment and placebo groups were comparable at entry for all demographic, clinical, and MRI variables. Treatment with GA showed a significant reduction in the total number of enhancing lesions compared with placebo (−10.8, 95% confidence interval −18.0 to −3.7; p = 0.003). Consistent differences favoring treatment with GA were seen for almost all secondary end points examined: number of new enhancing lesions (p < 0.003), monthly change in the volume of enhancing lesions (p = 0.01), and change in volume (p = 0.006) and number of new lesions seen on T2-weighted images (p < 0.003). The relapse rate was also significantly reduced by 33% for GA-treated patients (p = 0.012). All effects increased over time. Glatiramer acetate significantly reduced MRI-measured disease activity and burden. Ann Neurol 2001;49:290–297" @default.
• W4366064463 created "2023-04-18" @default.
• W4366064463 creator A5018024307 @default.
• W4366064463 creator A5040220962 @default.
• W4366064463 creator A5076338840 @default.
• W4366064463 date "2001-01-01" @default.
• W4366064463 modified "2023-10-17" @default.
• W4366064463 title "European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis" @default.
• W4366064463 cites W1967507425 @default.
• W4366064463 cites W1981866033 @default.
• W4366064463 cites W1982787660 @default.
• W4366064463 cites W1989217326 @default.
• W4366064463 cites W1992232972 @default.
• W4366064463 cites W1998308647 @default.
• W4366064463 cites W1998455368 @default.
• W4366064463 cites W2005506388 @default.
• W4366064463 cites W2008120870 @default.
• W4366064463 cites W2015916378 @default.
• W4366064463 cites W2017449946 @default.
• W4366064463 cites W2019237986 @default.
• W4366064463 cites W2023385152 @default.
• W4366064463 cites W2026464828 @default.
• W4366064463 cites W2029817323 @default.
• W4366064463 cites W2030792741 @default.
• W4366064463 cites W2036164613 @default.
• W4366064463 cites W2044149565 @default.
• W4366064463 cites W2044173905 @default.
• W4366064463 cites W2047354468 @default.
• W4366064463 cites W2066077179 @default.
• W4366064463 cites W2066124230 @default.
• W4366064463 cites W2090748566 @default.
• W4366064463 cites W2100721517 @default.
• W4366064463 cites W2103970051 @default.
• W4366064463 cites W2112165124 @default.
• W4366064463 cites W2130355701 @default.
• W4366064463 cites W2139367012 @default.
• W4366064463 cites W2141185335 @default.
• W4366064463 cites W2169098250 @default.
• W4366064463 cites W2171907184 @default.
• W4366064463 cites W2321043971 @default.
• W4366064463 doi "https://doi.org/10.1002/ana.64" @default.
• W4366064463 hasPublicationYear "2001" @default.
• W4366064463 type Work @default.
• W4366064463 citedByCount "399" @default.
• W4366064463 countsByYear W43660644632012 @default.
• W4366064463 countsByYear W43660644632013 @default.
• W4366064463 countsByYear W43660644632014 @default.
• W4366064463 countsByYear W43660644632015 @default.
• W4366064463 countsByYear W43660644632016 @default.
• W4366064463 countsByYear W43660644632017 @default.
• W4366064463 countsByYear W43660644632018 @default.
• W4366064463 countsByYear W43660644632019 @default.
• W4366064463 countsByYear W43660644632020 @default.
• W4366064463 countsByYear W43660644632021 @default.
• W4366064463 countsByYear W43660644632022 @default.
• W4366064463 countsByYear W43660644632023 @default.
• W4366064463 crossrefType "journal-article" @default.
• W4366064463 hasAuthorship W4366064463A5018024307 @default.
• W4366064463 hasAuthorship W4366064463A5040220962 @default.
• W4366064463 hasAuthorship W4366064463A5076338840 @default.
• W4366064463 hasConcept C118552586 @default.
• W4366064463 hasConcept C126322002 @default.
• W4366064463 hasConcept C126838900 @default.
• W4366064463 hasConcept C141071460 @default.
• W4366064463 hasConcept C142724271 @default.
• W4366064463 hasConcept C143409427 @default.
• W4366064463 hasConcept C168563851 @default.
• W4366064463 hasConcept C204787440 @default.
• W4366064463 hasConcept C27081682 @default.
• W4366064463 hasConcept C2778577042 @default.
• W4366064463 hasConcept C2780640218 @default.
• W4366064463 hasConcept C2781156865 @default.
• W4366064463 hasConcept C2989005 @default.
• W4366064463 hasConcept C44249647 @default.
• W4366064463 hasConcept C535046627 @default.
• W4366064463 hasConcept C71924100 @default.
• W4366064463 hasConceptScore W4366064463C118552586 @default.
• W4366064463 hasConceptScore W4366064463C126322002 @default.
• W4366064463 hasConceptScore W4366064463C126838900 @default.
• W4366064463 hasConceptScore W4366064463C141071460 @default.
• W4366064463 hasConceptScore W4366064463C142724271 @default.
• W4366064463 hasConceptScore W4366064463C143409427 @default.
• W4366064463 hasConceptScore W4366064463C168563851 @default.
• W4366064463 hasConceptScore W4366064463C204787440 @default.
• W4366064463 hasConceptScore W4366064463C27081682 @default.
• W4366064463 hasConceptScore W4366064463C2778577042 @default.
• W4366064463 hasConceptScore W4366064463C2780640218 @default.
• W4366064463 hasConceptScore W4366064463C2781156865 @default.
• W4366064463 hasConceptScore W4366064463C2989005 @default.
• W4366064463 hasConceptScore W4366064463C44249647 @default.
• W4366064463 hasConceptScore W4366064463C535046627 @default.
• W4366064463 hasConceptScore W4366064463C71924100 @default.
• W4366064463 hasIssue "3" @default.
• W4366064463 hasLocation W43660644631 @default.
• W4366064463 hasOpenAccess W4366064463 @default.
• W4366064463 hasPrimaryLocation W43660644631 @default.
• W4366064463 hasRelatedWork W102576517 @default.
• W4366064463 hasRelatedWork W1620159237 @default.

• next